Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity

Biochemical Journal

Volumn 468, Issue 1, 2015, Pages 125-132

  Ford, Rebecca J ^a   Fullerton, Morgan D ^a   Pinkosky, Stephen L ^a   Day, Emily A ^a   Scott, John W ^b   Oakhill, Jonathan S ^b   Bujak, Adam L ^a   Smith, Brennan K ^a   Crane, Justin D ^a   Blümer, Regje M ^a   Marcinko, Katarina ^a   Kemp, Bruce E ^b   Gerstein, Hertzel C ^a   Steinberg, Gregory R ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acetyl CoA carboxylase; Aspirin; Non alcoholic fatty liver disease; Salsalate; Type 2 diabetes

Indexed keywords

ACYL COENZYME A; ADENOSINE PHOSPHATE ACTIVATED PROTEIN KINASE BETA 1; BIOLOGICAL MARKER; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LIPID; METFORMIN; PROINSULIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SALSALATE; UNCLASSIFIED DRUG; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; CARDIOTONIC AGENT; PRKAB1 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DYSGLYCEMIA; ENERGY EXPENDITURE; ENZYME ACTIVATION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FEMALE; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; LIPID LIVER LEVEL; LIPOGENESIS; LIVER CELL; LOW DRUG DOSE; MALE; MIDDLE AGED; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CELL CULTURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; LIVER; METABOLISM;

MUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ASPIRIN; CARDIOTONIC AGENTS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DRUG SYNERGISM; ENZYME ACTIVATION; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPOGENESIS; LIVER; MALE; METFORMIN; MICE; MICE, INBRED C57BL;

EID: 84930606184     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20150125     Document Type: Article

References (43)

1. Cusi, K. (2012) Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142, 711-725 e716
2. Lambert, J. E., Ramos-Roman, M. A., Browning, J. D. and Parks, E. J. (2014) Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146, 726-735
3. Perry, R. J., Samuel, V. T., Petersen, K. F. and Shulman, G. I. (2014) The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84-91
4. Ruderman, N. B., Carling, D., Prentki, M. and Cacicedo, J. M. (2013) AMPK, insulin resistance, and the metabolic syndrome. J. Clin. Invest. 123, 2764-2772
5. Carling, D., Clarke, P. R., Zammit, V. A. and Hardie, D. G. (1989) Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur. J. Biochem. 186, 129-136
6. Fullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z. P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M. et al. (2013) Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 19, 1649-1654
7. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N. et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174
8. Hawley, S. A., Fullerton, M. D., Ross, F. A., Schertzer, J. D., Chevtzoff, C., Walker, K. J., Peggie, M. W., Zibrova, D., Green, K. A., Mustard, K. J. et al. (2012) The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336, 918-922
9. Bailey, C. J. and Turner, R. C. (1996) Metformin. N. Engl. J. Med. 334, 574-579
10. Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z. W., Karin, M. and Shoelson, S. E. (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293, 1673-1677
11. Meex, R. C., Phielix, E., Moonen-Kornips, E., Schrauwen, P. and Hesselink, M. K. (2011) Stimulation of human whole-body energy expenditure by salsalate is fueled by higher lipid oxidation under fasting conditions and by higher oxidative glucose disposal under insulin-stimulated conditions. J. Clin. Endocrinol. Metab. 96, 1415-1423
12. Pfutzner, A., Kunt, T., Hohberg, C., Mondok, A., Pahler, S., Konrad, T., Lubben, G. and Forst, T. (2004) Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 27, 682-687
13. Tsai, C. Y., Lin, Y. S., Yeh, T. S., Cheong, C. F., Chang, C. H., Chen, T. C. and Chen, M. F. (2011) Disrupted hepatic adiponectin signaling impairs liver regeneration of steatotic rats. Chang Gung Med. J. 34, 248-259 PubMed
14. Gerstein, H. C., Bosch, J., Dagenais, G. R., Diaz, R., Jung, H., Maggioni, A. P., Pogue, J., Probstfield, J., Ramachandran, A., Riddle, M. C. et al. (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367, 319-328
15. Fullerton, M. D., Hakimuddin, F., Bonen, A. and Bakovic, M. (2009) The development of a metabolic disease phenotype in CTP: phosphoethanolamine cytidylyltransferase-deficient mice. J. Biol. Chem. 284, 25704-25713
16. Dzamko, N., Van Denderen, B. J., Hevener, A. L., Jorgensen, S. B., Honeyman, J., Galic, S., Chen, Z. P., Watt, M. J., Campbell, D. J., Steinberg, G. R. and Kemp, B. E. (2010) AMPK beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. J. Biol. Chem. 285, 115-122
17. Chou, T. C. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446
18. Chou, T. C. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681
19. Ducommun, S., Ford, R. J., Bultot, L., Deak, M., Bertrand, L., Kemp, B. E., Steinberg, G. R. and Sakamoto, K. (2014) Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662. Am. J. Physiol. Endocrinol. Metab. 306, E688-696
20. Scott, J. W., Ling, N., Issa, S. M., Dite, T. A., O'Brien, M. T., Chen, Z. P., Galic, S., Langendorf, C. G., Steinberg, G. R., Kemp, B. E. and Oakhill, J. S. (2014) Small molecule drug A-769662 and AMP synergistically activate naive AMPK independent of upstream kinase signaling. Chem. Biol. 21, 619-627
21. Glass, D. B., Masaracchia, R. A., Feramisco, J. R. and Kemp, B. E. (1978) Isolation of phosphorylated peptides and proteins on ion exchange papers. Anal. Biochem. 87, 566-575
22. Galic, S., Fullerton, M. D., Schertzer, J. D., Sikkema, S., Marcinko, K., Walkley, C. R., Izon, D., Honeyman, J., Chen, Z. P., Van Denderen, B. J. et al. (2011) Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Invest. 121, 4903-4915
23. Gowans, G. J., Hawley, S. A., Ross, F. A. and Hardie, D. G. (2013) AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab. 18, 556-566
24. Wilcock, C. and Bailey, C. J. (1994) Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24, 49-57
25. Ruffin, M. T.t., Krishnan, K., Rock, C. L., Normolle, D., Vaerten, M. A., Peters-Golden, M., Crowell, J., Kelloff, G., Boland, C. R. and Brenner, D. E. (1997) Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J. Natl. Cancer Inst. 89, 1152-1160
26. Stephenne, X., Foretz, M., Taleux, N., Van Der Zon, G. C., Sokal, E., Hue, L., Viollet, B. and Guigas, B. (2011) Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 54, 3101-3110
27. El-Mir, M. Y., Nogueira, V., Fontaine, E., Averet, N., Rigoulet, M. and Leverve, X. (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223-228
28. Fulgencio, J. P., Kohl, C., Girard, J. and Pegorier, J. P. (2001) Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes. Biochem. Pharmacol. 62, 439-446
29. Collier, C. A., Bruce, C. R., Smith, A. C., Lopaschuk, G. and Dyck, D. J. (2006) Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 291, E182-E189
30. Tucker, G. T., Casey, C., Phillips, P. J., Connor, H., Ward, J. D. and Woods, H. F. (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br. J. Clin. Pharmacol. 12, 235-246
31. Pentikainen, P. J., Neuvonen, P. J. and Penttila, A. (1979) Pharmacokinetics of metformin after intravenous and oral administration to man. Eur. J. Clin. Pharmacol. 16, 195-202
32. Hundal, R. S., Petersen, K. F., Mayerson, A. B., Randhawa, P. S., Inzucchi, S., Shoelson, S. E. and Shulman, G. I. (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109, 1321-1326
33. Fleischman, A., Shoelson, S. E., Bernier, R. and Goldfine, A. B. (2008) Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31, 289-294
34. Frayn, K. N. (1983) Calculation of substrate oxidation rates in vivo from gaseous exchange. J. Appl. Physiol.: Respir. Environ. Exerc. Physiol. 55, 628-634 PubMed
35. Savage, D. B., Petersen, K. F. and Shulman, G. I. (2007) Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 87, 507-520
36. Wilke, M. S., French, M. A., Goh, Y. K., Ryan, E. A., Jones, P. J. and Clandinin, M. T. (2009) Synthesis of specific fatty acids contributes to VLDL-triacylglycerol composition in humans with and without type 2 diabetes. Diabetologia 52, 1628-1637
37. Marques-Lopes, I., Ansorena, D., Astiasaran, I., Forga, L. and Martinez, J. A. (2001) Postprandial de novo lipogenesis and metabolic changes induced by a high-carbohydrate, low-fat meal in lean and overweight men. Am. J. Clin. Nutr. 73, 253-261 PubMed
38. Zang, M., Zuccollo, A., Hou, X., Nagata, D., Walsh, K., Herscovitz, H., Brecher, P., Ruderman, N. B. and Cohen, R. A. (2004) AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. 279, 47898-47905
39. Beynen, A. C., Buechler, K. F., Van Der Molen, A. J. and Geelen, M. J. (1982) Inhibition of hepatic lipogenesis by salicylate. Toxicology 24, 33-43
40. Jung, T. W., Youn, B. S., Choi, H. Y., Lee, S. Y., Hong, H. C., Yang, S. J., Yoo, H. J., Kim, B. H., Baik, S. H. and Choi, K. M. (2013) Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A. Biochem. Pharmacol. 86, 960-969
41. Natali, A. and Ferrannini, E. (2006) Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49, 434-441
42. Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J. and Shoelson, S. E. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183-190
43. Goldfine, A. B., Silver, R., Aldhahi, W., Cai, D., Tatro, E., Lee, J. and Shoelson, S. E. (2008) Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin. Transl. Sci. 1, 36-43